Gervazyuk Olga
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Gervazyuk Olga has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Vorobey Ludmila
Shupyk National Healthcare University of Ukraine, Kyiv
2 shared publications - A.B. Boiko
Національний університет охорони здоров’я України імені П.Л. Шупика, м. Київ
1 shared publication - Anatoliy V. Kaminskiy
Shupyk National Healthcare University of Ukraine, Kyiv
1 shared publication Fastovec Alexandra
Національний університет охорони здоров’я України імені П. Л. Шупика, Україна
1 shared publication- Oleksii Zhdanovych
Shupyk National Healthcare University of Ukraine, Kyiv
1 shared publication - R.O. Tkachenko
P.L. Shupyk National Healthcare University of Ukraine, Kyiv, Ukraine
1 shared publication
Latest Publications
- Open Access
- 25 March 2022
- Published by RS Global Sp. z O.O. in World Science
- No. 3(75)
OBSTETRICS AND PERINATAL COMPLICATIONS IN PREGNANT WOMEN WITH CHORIOAMNIONITIS
Despite the development of innovative technologies, chorioamnionitis remains a pressing problem in modern obstetrics. The aim of our study was to determine the frequency of obstetric and perinatal complications in pregnant women with chorioamnionitis. The objective of our study was to determine the frequency of obstetrics and perinatal complications in pregnant women with chorioamnionitis. Study groups were formed: Group I (main) - 100 pregnant women with chorioamnionitis, Group II (control) - 100 women with physiological pregnancy. The condition of the mother-placenta-fetus system and the functional fetal condition were assessed by Doppler ultrasound and cardiotocography. The analysis of perinatal consequences in pregnant women with chorioamnionitis was performed, in particular, a retrospective study of perinatal mortality. In the main group of patients were observed the structural changes in placenta 3.9 times more than in group II, oligohydramnios and polyhydramnios 6.9 and 5.6 times more, respectively, intrauterine growth retardation stage I was observed in 11.0% of studied in the main group, intrauterine growth retardation stage II and III were found only in pregnant women of group I (54.0% and 6.0%), respectively. In the hemodynamic disorders structure is dominated by stage II, the degree ofdisorders is 62.0%, only in women with chorioamnionitis were observed disorders in the system "mother-placenta-fetus" stage III - 9.0%.Cardiotocography analysis defined signs of fetal cardiac reactivity in 85.0% of patients. The pathological course of childbirth significantly prevailed in the studied of the main group. Intrauterine infection was diagnosed in 21.0% of cases. Early neonatal sepsis was observed in 9 (42.9%) cases, necrotizing enterocolitis in 5 (23.8%) newborns, congenital pneumonia - 7 (33.3%) cases. In the structure of antenatal fetal death, chorioamnionitis in pregnant women was diagnosed in 63.6% of patients, in the structure of early neonatal mortality - 58.3% of cases. The results of the study indicate that intraamniotic infection is a risk factor for the development of pathological pregnancy and labor with relevant perinatal complications.
- 25 March 2022
- Published by RS Global Sp. z O.O. in World Science
- No. 3(75)
Open AccessOBSTETRICS AND PERINATAL COMPLICATIONS IN PREGNANT WOMEN WITH CHORIOAMNIONITIS
Despite the development of innovative technologies, chorioamnionitis remains a pressing problem in modern obstetrics. The aim of our study was to determine the frequency of obstetric and perinatal complications in pregnant women with chorioamnionitis. The objective of our study was to determine the frequency of obstetrics and perinatal complications in pregnant women with chorioamnionitis. Study groups were formed: Group I (main) - 100 pregnant women with chorioamnionitis, Group II (control) - 100 women with physiological pregnancy. The condition of the mother-placenta-fetus system and the functional fetal condition were assessed by Doppler ultrasound and cardiotocography. The analysis of perinatal consequences in pregnant women with chorioamnionitis was performed, in particular, a retrospective study of perinatal mortality. In the main group of patients were observed the structural changes in placenta 3.9 times more than in group II, oligohydramnios and polyhydramnios 6.9 and 5.6 times more, respectively, intrauterine growth retardation stage I was observed in 11.0% of studied in the main group, intrauterine growth retardation stage II and III were found only in pregnant women of group I (54.0% and 6.0%), respectively. In the hemodynamic disorders structure is dominated by stage II, the degree ofdisorders is 62.0%, only in women with chorioamnionitis were observed disorders in the system "mother-placenta-fetus" stage III - 9.0%.Cardiotocography analysis defined signs of fetal cardiac reactivity in 85.0% of patients. The pathological course of childbirth significantly prevailed in the studied of the main group. Intrauterine infection was diagnosed in 21.0% of cases. Early neonatal sepsis was observed in 9 (42.9%) cases, necrotizing enterocolitis in 5 (23.8%) newborns, congenital pneumonia - 7 (33.3%) cases. In the structure of antenatal fetal death, chorioamnionitis in pregnant women was diagnosed in 63.6% of patients, in the structure of early neonatal mortality - 58.3% of cases. The results of the study indicate that intraamniotic infection is a risk factor for the development of pathological pregnancy and labor with relevant perinatal complications.
- Open Access
- 29 December 2021
- Published by Publishing Office TRILIST in Reproductive Endocrinology
- No. 62,p. 8-13
Therapeutic opportunities for improving the course of coronavirus disease and reducing the frequency of gestional complications
Research objective: to study the clinical efficacy of the proposed treatment complex in pregnant women with coronavirus disease (COVID-19).Materials and methods. 60 pregnant women with a moderate COVID-19 who were treated at the Kyiv City Center for Reproductive and Perinatal Medicine were examined and selected to assess the effectiveness of the proposed treatment. Pregnant women were divided into 2 clinical groups: the main group (n = 30) were prescribed treatment complex with progestin, the comparison group consisted of 30 pregnant women with COVID-19, who did not differ in age, sex, body mass index and received only standard drug therapy. Given the immunomodulatory effect, micronized progesterone was administered orally 200 mg three times a day immediately after hospitalization for 2 weeks, regardless of gestational age. Clinical manifestations, laboratory and instrumental indicators, duration of oxygen therapy and respiratory support, duration of hospital stay and intensive care were analyzed to assess the treatment complex.Results. Therapeutic complex with progesterone helps to reduce the severity of respiratory disorders in pregnant women with COVID-19, the general condition of pregnant women improves faster and inflammatory changes in the lungs regress. The positive dynamics of pulse oximetry indicators was noted. The frequency of the additional methods of respiratory support and transfer to the intensive care unit were lower, and a more rapid normalization of laboratory parameters was noted. Incidence of gestational complications (threats of pregnancy termination, placental insufficiency, fetal growth retardation and distress, oligohydramnios, premature birth and premature rupture of membranes) was lower against the background of treatment with progesterone, children status was better at birth. The need for oxygen therapy, the length of stay in the intensive care unit and the total length of hospitalization are significantly reduced when progesterone was prescribed for pregnant women with COVID-19.Conclusions. The use of progesterone in pregnant women with coronavirus disease has a stabilizing effect, has no negative side effects which is significantly expands the scope of the proposed therapy in pregnant women at different stages of gestation.
- 29 December 2021
- Published by Publishing Office TRILIST in Reproductive Endocrinology
- No. 62,p. 8-13
Open AccessTherapeutic opportunities for improving the course of coronavirus disease and reducing the frequency of gestional complications
Research objective: to study the clinical efficacy of the proposed treatment complex in pregnant women with coronavirus disease (COVID-19).Materials and methods. 60 pregnant women with a moderate COVID-19 who were treated at the Kyiv City Center for Reproductive and Perinatal Medicine were examined and selected to assess the effectiveness of the proposed treatment. Pregnant women were divided into 2 clinical groups: the main group (n = 30) were prescribed treatment complex with progestin, the comparison group consisted of 30 pregnant women with COVID-19, who did not differ in age, sex, body mass index and received only standard drug therapy. Given the immunomodulatory effect, micronized progesterone was administered orally 200 mg three times a day immediately after hospitalization for 2 weeks, regardless of gestational age. Clinical manifestations, laboratory and instrumental indicators, duration of oxygen therapy and respiratory support, duration of hospital stay and intensive care were analyzed to assess the treatment complex.Results. Therapeutic complex with progesterone helps to reduce the severity of respiratory disorders in pregnant women with COVID-19, the general condition of pregnant women improves faster and inflammatory changes in the lungs regress. The positive dynamics of pulse oximetry indicators was noted. The frequency of the additional methods of respiratory support and transfer to the intensive care unit were lower, and a more rapid normalization of laboratory parameters was noted. Incidence of gestational complications (threats of pregnancy termination, placental insufficiency, fetal growth retardation and distress, oligohydramnios, premature birth and premature rupture of membranes) was lower against the background of treatment with progesterone, children status was better at birth. The need for oxygen therapy, the length of stay in the intensive care unit and the total length of hospitalization are significantly reduced when progesterone was prescribed for pregnant women with COVID-19.Conclusions. The use of progesterone in pregnant women with coronavirus disease has a stabilizing effect, has no negative side effects which is significantly expands the scope of the proposed therapy in pregnant women at different stages of gestation.
- Open Access
- 25 March 2020
- Published by Publishing Office TRILIST in Reproductive Endocrinology
- No. 51,p. 47-50
The state of the fibrinolytic system in HIV-infected pregnant women and parturient women with thrombohemorrhagic risk factors
Purpose of the study: to explore the status of the fibrinolytic system in HIV-infected pregnant women and parturient women.Materials and methods. 120 HIV-positive pregnant women with risk factors of thrombohemorrhagic complications were examined. The main group included: IA-O subgroup – 10 patients with HIV-infection stage I who received high-activity antiretroviral therapy before this pregnancy, IB-O subgroup – 20 patients with HIV-infection stage I who started high-activity antiretroviral therapy during this pregnancy, II-O – 21 pregnant women with HIV infection II clinical stage, III-O subgroup – 24 women with HIV-infection III clinical stage. Comparison group consisted of 45 patients with HIV infection without thrombohemorrhagic complications; control group consisted of 40 pregnant women and parturient women without HIV. D-dimer, soluble fibrin-monomer complexes, antithrombin III and XIIa-dependent fibrinolysis time were evaluated.Study results. In II-O and III-O subgroups there were changes of fibrinolytic system state in 18–22 weeks of pregnancy – increased D-dimer and soluble fibrin-monomer complexes, XIIa-dependent fibrinolysis time prolongation and antithrombin III decreased. With pregnancy progression the main group with HIV stage III showed a significant increase of soluble fibrin-monomer complexes and D-dimer with a tendency to XIIa-dependent fibrinolysis time reduction and antithrombin III decreasing. In all women of the main group there were thrombosis signs. In subgroup III-O there were laboratory signs of fibrinolysis activation (shortening the time of XIIa-dependent fibrinolysis) and a tendency to antithrombin III decrease. Parturient women who started taking high-activity antiretroviral therapy during this pregnancy show a slowing of the fibrinolysis processes (shortening of XIIa-dependent fibrinolysis) and a tendency to antithrombin III decrease. In IB-O subgroup there was a further suppression of fibrinolysis (prolonging the time of XIIa-dependent fibrinolysis).Conclusions. Changes in the fibrinolytic system toward suppression of the fibrinolysis process during pregnancy and it activation during labor are significantly present in HIV-infected pregnant women and in women with risk factors for thrombogemorrhagic complications.
- 25 March 2020
- Published by Publishing Office TRILIST in Reproductive Endocrinology
- No. 51,p. 47-50
Open AccessThe state of the fibrinolytic system in HIV-infected pregnant women and parturient women with thrombohemorrhagic risk factors
Purpose of the study: to explore the status of the fibrinolytic system in HIV-infected pregnant women and parturient women.Materials and methods. 120 HIV-positive pregnant women with risk factors of thrombohemorrhagic complications were examined. The main group included: IA-O subgroup – 10 patients with HIV-infection stage I who received high-activity antiretroviral therapy before this pregnancy, IB-O subgroup – 20 patients with HIV-infection stage I who started high-activity antiretroviral therapy during this pregnancy, II-O – 21 pregnant women with HIV infection II clinical stage, III-O subgroup – 24 women with HIV-infection III clinical stage. Comparison group consisted of 45 patients with HIV infection without thrombohemorrhagic complications; control group consisted of 40 pregnant women and parturient women without HIV. D-dimer, soluble fibrin-monomer complexes, antithrombin III and XIIa-dependent fibrinolysis time were evaluated.Study results. In II-O and III-O subgroups there were changes of fibrinolytic system state in 18–22 weeks of pregnancy – increased D-dimer and soluble fibrin-monomer complexes, XIIa-dependent fibrinolysis time prolongation and antithrombin III decreased. With pregnancy progression the main group with HIV stage III showed a significant increase of soluble fibrin-monomer complexes and D-dimer with a tendency to XIIa-dependent fibrinolysis time reduction and antithrombin III decreasing. In all women of the main group there were thrombosis signs. In subgroup III-O there were laboratory signs of fibrinolysis activation (shortening the time of XIIa-dependent fibrinolysis) and a tendency to antithrombin III decrease. Parturient women who started taking high-activity antiretroviral therapy during this pregnancy show a slowing of the fibrinolysis processes (shortening of XIIa-dependent fibrinolysis) and a tendency to antithrombin III decrease. In IB-O subgroup there was a further suppression of fibrinolysis (prolonging the time of XIIa-dependent fibrinolysis).Conclusions. Changes in the fibrinolytic system toward suppression of the fibrinolysis process during pregnancy and it activation during labor are significantly present in HIV-infected pregnant women and in women with risk factors for thrombogemorrhagic complications.